A “Low Dose Aspirin” for Dementia? Drug Ready for First in-Human Testing

Summary: MW-151, a new drug that blocks ‘bad’ inflammation in the brain is about to be tested in a new human trial. Researchers believe the new drug could help stave off dementia.

Source: University of Kentucky

Alzheimer’s disease wreaks emotional havoc on patients, who are robbed of their memories, their dignity, and their lives. It’s financially devastating as well: care for Alzheimer’s patients is predicted to top $1 trillion by about the time children born today are having children of their own.

To date, there have been very few successes in the pursuit of treatment. But one drug that looks at Alzheimer’s Disease (AD) from a different angle is now ready for its first round of testing in humans.

The vast majority of AD treatments that are currently FDA-approved or in the pipeline target amyloid, which is responsible for the hallmark plaques that interfere with cognition. As the so-called “Amyloid Theory” has produced one drug failure after another, scientists have begun to explore other therapeutic avenues. Linda Van Eldik, Director of the Sanders-Brown Center on Aging at the University of Kentucky, has set her sights on an understudied, but (in her view) more promising target: brain inflammation.

“Inflammation is normally a ‘good guy.’ It clears infections and helps heal wounds, for example,” said Van Eldik. “But in Alzheimer’s disease, the inflammation somehow gets out of whack. It gets too strong and sustains for too long — it’s now turned into a ‘bad guy,’ destroying the neurons that carry signals from one part of the brain to the next.”

Van Eldik began collaborating with Martin Watterson at Northwestern University to identify a drug that would block the “bad” inflammation in the brain without affecting the “good” inflammation that helps jumpstart repair.

After years of research, Van Eldik is ready to test this drug — enigmatically named MW-151 — in humans. Both the National Institutes of Health and the Alzheimer’s Drug Discovery Foundation are sufficiently intrigued that they’ve bet a combined $5.5 million to underwrite her efforts.

This is quite an accomplishment: current estimates say that for every 5,000 to 10,000 compounds that enter the drug discovery process, only five will go into a human clinical trial.

Even if MW-151 beats the considerable odds that confront every potential new drug, it’s years away from being available to the public. If the drug ultimately proves safe and effective, Van Eldik believes that MW-151 will function as a once-daily pill that staves off dementia, much like a baby aspirin prescribed to prevent heart attack or stroke.

This shows pills and a pestle and mortar

Even if MW-151 beats the considerable odds that confront every potential new drug, it’s years away from being available to the public. If the drug ultimately proves safe and effective, Van Eldik believes that MW-151 will function as a once-daily pill that staves off dementia, much like a baby aspirin prescribed to prevent heart attack or stroke. The image is in the public domain.

That could be a game-changer in the fight against AD. According to the Alzheimer’s Association, delaying the onset of dementia by just five years would cut the incidence almost in half, which translates to enormous financial and emotional savings for patients and their families.

Van Eldik does not consider MW-151 a silver bullet, however.

“This is a very complex disease ” she cautions. “A single approach — even our approach against inflammation — may not be enough.”


Video credit: University of Kentucky.

“I think this drug it will be most effective as part of a ‘cocktail’ of drugs that target multiple mechanisms of the disease. If that worked out, boy, that would be a slam dunk.”

About this neuroscience research article

Source:
University of Kentucky
Media Contacts:
Laura Wright – University of Kentucky
Image Source:
The image is in the public domain.

Feel free to share this Neuroscience News.
Join our Newsletter
I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information )
Sign up to receive the latest neuroscience headlines and summaries sent to your email daily from NeuroscienceNews.com
We hate spam and only use your email to contact you about newsletters. We do not sell email addresses. You can cancel your subscription any time.